Results 121 to 130 of about 11,782,455 (235)
Aloperin improves liver non-alcoholic steatohepatitis in vitro and in vivo
Introduction The aim of this work is to investigate the inhibitory effect of aloperin (Alo) on hepatocyte apoptosis in non-alcoholic fatty liver disease, and the underlying mechanism.
Sumei Lu +6 more
core +1 more source
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) has emerged as the most prevalent chronic liver disease worldwide, closely linked to the global rising incidence of obesity and metabolic syndrome. This review synthesizes current evidence on the pathogenesis, gut–liver axis, and multidisciplinary management of MASLD within the ...
Beom Kyung Kim
wiley +1 more source
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is increasingly prevalent among lean Asian populations, yet effective strategies for identifying high‐risk individuals remain limited. We investigated the associations of body fat percentage (BF%) and the triglyceride‐glucose (TyG) index with lean MASLD and evaluated their ...
Xiang‐Ran Kong +4 more
wiley +1 more source
ABSTRACT The prognostic effect of concurrent metabolic dysfunction‐associated steatotic liver disease (MASLD) on outcomes for hepatocellular carcinoma (HCC) patients remains unclear. The Prognostic Nutritional Index (PNI) reflects nutritional and inflammatory status and is a well‐known prognostic factor.
Chun‐Ting Ho +10 more
wiley +1 more source
[Non alcoholic steatohepatitis].
A prospective study of 21 patients with the diagnosis of non-alcoholic steatohepatitis (NASH) was carried out. All patients had hepatomegaly and in 10 (48%) image studies were consistent with steatosis and/or fibrosis. Biochemically, there was increase of AST, ALT and cholesterol in 48%, of GGT in 52% and of alkaline phosphatase in 38%.
E, Manero +4 more
openaire +1 more source
ABSTRACT The impacts of cardiometabolic risk factors (CMRFs) and the biomarkers on disease severity in metabolic dysfunction‐associated steatotic liver disease (MASLD) remain elusive. Accordingly, a multicenter study by recruiting MASLD patients from a nationwide registry database was conducted with a total of 2882 MASLD patients (54.1% males, mean age
Jee‐Fu Huang +14 more
wiley +1 more source
Non-alcoholic steatohepatitis (NASH) animal model
This is an experimental animal model that mimics human non-alcoholic steatohepatitis (NASH). In this model, we used a 12% cholesterol diet together with a choline mixture to be induced in rats for 16 consecutive weeks.
Abdul Rahim, Roslina +4 more
core
[Non-alcoholic steatohepatitis].
There is a growing interest in nonalcoholic steatohepatitis (NASH), a disease entity which is quite similar to alcoholic liver disease.We present three patients with nonalcoholic steatohepatitis, and review current opinion on this disease entity.Non-alcoholic steatohepatitis is very often associated with the insulin resistance syndrome.
J W, Haukeland +3 more
openaire +3 more sources
This review systematically compares the size‐dependent toxicity of microplastics and nanoplastics in the intestine, liver, kidney, lung, and brain. Particle size determines bioavailability, barrier penetration, and injury mechanisms. Because of their small size and high surface reactivity, NPs readily cross the intestinal epithelium and blood–brain ...
Yixian Cheng +14 more
wiley +1 more source
The role of tryptophan hydroxylase‐1 in metabolic dysfunction‐associated steatotic liver disease
Silencing hepatic tryptophan hydroxylase 1 (TPH1) alleviated diet‐induced steatotic liver disease by reducing lipid accumulation, oxidative stress, inflammation, fibrosis, and hepatocyte apoptosis. These protective effects were mediated, at least in part, through restoration of Parkin‐dependent mitochondrial autophagy, identifying hepatic TPH1 as a ...
Shuangzhen Jia +3 more
wiley +1 more source

